These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

946 related articles for article (PubMed ID: 30404198)

  • 1. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
    Jiang W; Ji M
    Semin Cancer Biol; 2019 Dec; 59():3-22. PubMed ID: 30943434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
    Montor WR; Salas AROSE; Melo FHM
    Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired resistance to drugs targeting receptor tyrosine kinases.
    Rosenzweig SA
    Biochem Pharmacol; 2012 Apr; 83(8):1041-8. PubMed ID: 22227013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S; Crescenzi E; Fedele M; Cerchia L
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.
    Iams WT; Lovly CM
    Clin Cancer Res; 2015 Oct; 21(19):4270-7. PubMed ID: 26429980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic advances of targeting receptor tyrosine kinases in cancer.
    Tomuleasa C; Tigu AB; Munteanu R; Moldovan CS; Kegyes D; Onaciu A; Gulei D; Ghiaur G; Einsele H; Croce CM
    Signal Transduct Target Ther; 2024 Aug; 9(1):201. PubMed ID: 39138146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
    Hojjat-Farsangi M
    Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.
    Lakkakula BVKS; Farran B; Lakkakula S; Peela S; Yarla NS; Bramhachari PV; Kamal MA; Saddala MS; Nagaraju GP
    Semin Cancer Biol; 2019 Jun; 56():149-167. PubMed ID: 30314681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization.
    Bhattacharya P; Shetake NG; Pandey BN; Kumar A
    Int J Radiat Biol; 2018 Jul; 94(7):628-644. PubMed ID: 29775397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
    Borah NA; Reddy MM
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERBB receptors and cancer: the complexity of targeted inhibitors.
    Hynes NE; Lane HA
    Nat Rev Cancer; 2005 May; 5(5):341-54. PubMed ID: 15864276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.